Últimas noticias sobre Vaxcyte (NASDAQ:PCVX) Bolsa

Vaxcyte

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Vaxcyte Inc

Stifel analyst Parker Lane maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Buy and lowers the price target from $650 to $600.

News

Price Target

Analyst Ratings

ADBE

Stifel Maintains Buy on Adobe, Lowers Price Target to $600

Oppenheimer analyst Brian Schwartz maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Outperform and lowers the price target from $625 to $600.

Oppenheimer Maintains Outperform on Adobe, Lowers Price Target to $600

EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026.
 &nbsp;

ELEV

Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate

Morgan Stanley analyst Nathan Feather maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Equal-Weight and lowers the price target from $33 to $31.

MTCH

Morgan Stanley Maintains Equal-Weight on Match Group, Lowers Price Target to $31

Morgan Stanley analyst Alex Straton maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Equal-Weight and lowers the price target from $17 to $16.

Morgan Stanley Maintains Equal-Weight on Macy's, Lowers Price Target to $16

The Monterey County District Attorney's Office is the fourth prosecutor's office in California to digitally transform evidence management with NICE Justice.

NICE

Monterey County District Attorney's Office Picks NICE Justice AI-Powered Digital Evidence Management

Macquarie analyst Steve Koenig initiates coverage on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Neutral rating and announces Price Target of $300.

Initiation

Macquarie Initiates Coverage On MongoDB with Neutral Rating, Announces Price Target of $300

Shares of&nbsp;Adobe Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) experienced a significant decline in pre-market trading on Thursday, following the company&#8217;s release of a revenue forecast that fell short of expectations.
The Photoshop maker saw its shares drop&nbsp;by 11.75% during pre-market hours&nbsp;on Thursday, according to&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a>. This decline followed a lackluster full-year revenue forecast, raising concerns about the timeline for returns on AI investments.
Adobe released its&nbsp;<a href="https://www.benzinga.com/news/earnings/24/12/42449013/adobe-q4-earnings-revenue-eps-beat-on-strong-demand-related-to-ai-shares-slide-following-soft-guidance">fourth-quarter financial results</a> after the&nbsp;market closed on Wednesday. The company reported revenue of $5.61 billion, surpassing&nbsp;the consensus estimate of $5.54&nbsp;billion. Adjusted earnings per share were $4.81, exceeding analyst predictions of $4.66 per share.
See Also:&nbsp;<a href="https://www.benzinga.com/news/global/24/12/42406893/bill-gates-could-go-bankrupt-if-tesla-stock-surges-200-to-become-the-top-company-says-elon-musk?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bill Gates Could Go Bankrupt If Tesla Stock Surges 200% To Become The Top Company, Says Elon Musk</a>
Despite beating estimates for eight consecutive quarters, Adobe&#8217;s guidance for the upcoming year fell short of expectations. The company anticipates first-quarter revenue between $5.63 billion and $5.68 billion, compared to estimates of $5.73 billion. Full-year 2025 revenue is expected to range from $23.3 billion to $23.55 billion, below the projected $23.79 billion.
Adobe&#8217;s stock faced selling pressure due to this soft guidance. The company plans to discuss the quarter further during a call with analysts and investors from 5 p.m. to 6 p.m. ET. RBC analyst Matthew Swanson told Reuters that the lack of explicit monetization metrics for Adobe&#8217;s GenAI product roadmap is a concern for investors.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42405504/dogecoin-can-touch-18-if-things-go-wild-says-influential-crypto-trader-thankful-for-the-dip-and-will-buy-more?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Can Touch $18 If Things &#8216;Go Wild,&#8217; Says Influential Crypto Trader: &#8216;Thankful For The Dip And Will Buy More&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

Adobe Shares Plunges Over 11% After Disappointing Revenue Forecast

ADBE: -11% &#x7C; <a href="https://www.benzinga.com//node/42448063">Adobe shares are trading lower following mixed guidance.</a>
&nbsp;
DBVT: 76% &#x7C; <a href="https://www.benzinga.com//node/42448378">DBC Technologies shares are trading higher after the company announced alignment with the FDA on an accelerated approval pathway for the Viaskin peanut patch in toddlers one to three years old.</a>
&nbsp;
ZENA: 41% &#x7C; <a href="https://www.benzinga.com//node/42458190">ZenaTech Announces The Launch Of A Quantum Computing Project For Traffic Optimization And Weather Forecasting Using The Company's Drones</a>

Movers

Trading Ideas

DBVT

ZENA

Market-Moving News for December 12th

GXAI

Gaxos.ai Integrates Recraft AI Into Their Artificial Intelligence Solution For Game Developers And Publishers, Gaxos Labs

Macquarie analyst Steve Koenig initiates coverage on Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Neutral rating and announces Price Target of $290.

TEAM

Macquarie Initiates Coverage On Atlassian with Neutral Rating, Announces Price Target of $290

By entering into this agreement with Sarborg, Conduit will address longstanding challenges in the pharmaceutical sector by seeking to reduce human error in critical decision-making processes including clinical development and asset identification.&nbsp;
Conduit will retain a perpetual, non-exclusive, royalty-free, and assignable right to use any platform or technology developed by Sarborg in association with the deliverables.&nbsp;

Conduit Pharmaceuticals Enters Agreement With Sarborg To Leverage AI And Cybernetics Platform To Evaluate Key Deliverables Across Multiple Areas Of Operations

The project, called Sky Traffic, was developed following interest received from a government client to use the company's ZenaDrone 1000 drones to monitor vehicle traffic

ZenaTech Announces The Launch Of A Quantum Computing Project For Traffic Optimization And Weather Forecasting Using The Company's Drones

Macquarie analyst Steve Koenig initiates coverage on GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform rating and announces Price Target of $90.

GTLB

Macquarie Initiates Coverage On GitLab with Outperform Rating, Announces Price Target of $90

Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) soared 22% in 24 hours, bringing its month-over-month performance to 93% as fundamental developments point to <a href="https://www.benzinga.com/money/chainlink-link-price-prediction">a bullish future.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>)</td>
<td>&nbsp;$27.80</td>
<td>$17.4 billion</td>
<td>+22%&nbsp;</td>
<td>&nbsp;+14.8%</td>
</tr>
<tr>
<td>Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>)</td>
<td>&nbsp;$49.86</td>
<td>$20.4 billion</td>
<td>&nbsp;+9.9%</td>
<td>&nbsp;-5.5%</td>
</tr>
<tr>
<td>TRON (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>)</td>
<td>&nbsp;$0.2963</td>
<td>$25.6 billion</td>
<td>&nbsp;+8.2%</td>
<td>&nbsp;-12.4%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Altcoin Sherpa advises traders to look for demand zones on lower timeframes, targeting $25 for short-term scalping. For longer-term positions, he suggests $24 as an ideal entry. "Still bullish on this one," he <a href="https://x.com/AltcoinSherpa/status/1867150656693285278">noted</a>.
Another veteran trader, Jacob Canfield, highlighted Chainlink's successful retest of its impulse breakout base, breaking local resistance, and called it "probably the start of the uptrend."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24LINK&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$LINK</a> &#8211; Base of the impulse breakout retested and just broke local resistance. This is probably the start of the uptrend. <a href="https://t.co/xl2HD1mB77">https://t.co/xl2HD1mB77</a> <a href="https://t.co/oWgK0ksUvL">pic.twitter.com/oWgK0ksUvL</a>
&mdash; Jacob Canfield (@JacobCanfield) <a href="https://twitter.com/JacobCanfield/status/1867082616987685195?ref_src=twsrc%5Etfw">December 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Santiment data shows that Chainlink crossed $29 for the first time in 37 months, driven by increased whale and shark accumulation. 
Large wallets holding more than 100,000 LINK have added 5.69 million LINK over two months, while smaller wallets (&lt;100,000 LINK) have sold off 5.67 million LINK.
Historically, such accumulation by large wallets often signals potential market cap growth. 
However, Chainlink's success remains tied to Bitcoin&#8217;s stability, with long-term holders likely to <a href="https://x.com/santimentfeed/status/1867151100320555304">benefit</a> if conditions remain favorable.
Statistics: Lookonchain data <a href="https://x.com/lookonchain/status/1867133609842532643">highlighted</a> that crypto whales are buying Chainlink as a whale spent 1,263 ETH, worth $4.94 million, to purchase 175,424 LINK at $28.18 in the past 5 hours. 
World Liberty Financial, the crypto project tied to President-elect Donald Trump, <a href="https://x.com/lookonchain/status/1867036708983935325">has purchased</a> Ethereum, Chainlink and Aave Finance. The wallet added 41,335 LINK at $24.2.
On this, crypto trader Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1867041625630970006">reacted</a> "the president buying LINK was in the charts all along, always was."
IntoTheBlock data shows Chainlink's large transaction volume is down 17% and daily active addresses are lower by 13% in single day. Exchanges netflows narrowed by 161.2%. Transactions greater than $100,000 dropped from 852 to 541 in single day.
With monthly gains of around 93%, around 83% LINK holders are in profit and 17% are at breakeven.
Community News: Chainlink's rally underscores its growing appeal among institutional and high-profile investors. Despite increased volatility, its fundamentals, including whale accumulation and partnerships, suggest long-term potential.
Chainlink and Coinbase <a href="https://www.prnewswire.com/news-releases/coinbases-project-diamond-strategically-integrates-the-chainlink-standard-to-scale-institutional-adoption-of-digital-assets-302327790.html">announced</a> that Coinbase's Project Diamond will adopt Chainlink's standards to power tokenized asset lifecycle management.
Emirates NBD, a leading banking group, added Chainlink as the fifth council member in its Digital Asset Lab, boosting its credibility in the financial sector.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42291401/chainlink-price-surges-15-in-one-day-why-is-link-going-up">Chainlink Price Surges 15% In One Day: Why Is LINK Going Up?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AVAX

$LINK

$TRX

Chainlink Price Soars 22% On President-Elect Donald Trump's World Liberty Financial Purchases: How High Can LINK Go?

Wells Fargo analyst Michael Brown downgrades Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) from Overweight to Equal-Weight and raises the price target from $188 to $195.

Downgrades

Wells Fargo Downgrades Blackstone to Equal-Weight, Raises Price Target to $195

As part of the integration process, the Company is conducting a comprehensive cost-reduction and product-line rationalization initiative. This effort is aimed at reducing expenses and further enhancing AstroNova's product portfolio.&nbsp;
AstroNova plans to discuss the results of this initiative, and provide long-term financial targets, on its full-year fiscal 2025 earnings call in March.

Guidance

ALOT

AstroNova Says It Is No Longer Providing Financial Guidance For Fiscal 2025 And 2026, Citing Extended Integration Timeline For MTEX Acquisition

Deutsche Bank analyst Pito Chickering upgrades Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Hold to Buy and raises the price target from $45 to $75.

Upgrades

ACHC

Deutsche Bank Upgrades Acadia Healthcare Co to Buy, Raises Price Target to $75

Editor&#8217;s Note: The story has been updated with additional bank executives in paragraph 5
The New York Police Department has issued a warning about escalating threats to healthcare executives, according to a report on Wednesday. This follows the murder of UnitedHealth Group Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) insurance unit UnitedHealthcare CEO Brian Thompson. The NYPD&#8217;s bulletin highlights the circulation of online posts listing the names and salaries of several health insurance executives, raising security concerns.
What Happened: The NYPD&#8217;s bulletin, as <a href="https://abcnews.go.com/US/executive-hit-lists-wanted-posters-nypd-warns-threats/story?id=116662519">reported</a> by&nbsp;ABC News, reveals that &#8220;Wanted&#8221;&nbsp;signs featuring corporate executives have&nbsp;appeared across Manhattan. Social media users have been celebrating Thompson&#8217;s death, and the suspect, Luigi Mangione, is being viewed by some as a &#8220;martyr&#8221; who could inspire extremist actions.
The bulletin warns that Mangione&#8217;s actions could incite violence from extremist groups. Companies are urged to enhance security measures for their executives. Mangione was apprehended in Pennsylvania on&nbsp;Monday and faces charges in&nbsp;New York, including second-degree murder.
Additionally, some online users have&nbsp;reacted positively to the killing,&nbsp;encouraged further&nbsp;targeting of similar executives, and&nbsp;spread conspiracy theories about the incident. Viral posts have emphasized a &#8220;hitlist&#8221; of health insurance CEOs, suggesting they should be fearful.
Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-12-11/cops-investigate-wanted-posters-of-executives-around-nyc">noted</a> that the posters in New York featured the images of insurance executives including the image of the Thompson, and several financial executives from American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and JP Morgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>). Thompson&#8217;s posters were marked with a red X.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/12/42404540/whats-going-on-with-dogecoin-rival-shiba-inu-shib-2?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Dogecoin Rival Shiba Inu (SHIB)?</a>
Why It Matters: The murder of&nbsp;UnitedHealthcare&nbsp;CEO Thompson last week, outside the New York Hilton Midtown, has sent shockwaves through the healthcare industry. The targeted <a href="https://www.benzinga.com/general/health-care/24/12/42316904/unitedhealthcare-ceo-brian-thompson-fatally-shot-outside-nyc-hotel">attack occurred</a> during an investor day event, raising questions about the safety of corporate executives.&nbsp;
Details about the suspect, Mangione, reveal a complex background, including chronic pain and a fascination with the Unabomber. This has added layers to the investigation.&nbsp;Mangione was <a href="https://www.benzinga.com/news/legal/24/12/42418763/unitedhealthcare-ceo-murder-suspect-chronic-pain-unabomber-fascination-isolation-details-emerge">arrested</a> in Pennsylvania&nbsp;with a ghost gun and silencer, matching the suspect&#8217;s description.&nbsp;
The incident has also <a href="https://www.benzinga.com/24/12/42365853/unitedhealthcare-faces-tough-questions-following-insurance-business-ceos-tragic-death">intensified scrutiny</a> on&nbsp;UnitedHealthcare&nbsp;and the broader insurance industry. Bullet casings found at the crime scene bore inscriptions like &#8220;deny&#8221; and &#8220;delay,&#8221; terms often associated with insurance claim practices. 
Price Action: On Wednesday UnitedHealth Group shares ended the day 5.6% lower at $533.53 and fell another 0.1% in the after-hours trading, according to <a href="http://pro.benzinga.com/">data from Benzinga Pro</a>.
Photo via Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42405504/dogecoin-can-touch-18-if-things-go-wild-says-influential-crypto-trader-thankful-for-the-dip-and-will-buy-more?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Can Touch $18 If Things &#8216;Go Wild,&#8217; Says Influential Crypto Trader: &#8216;Thankful For The Dip And Will Buy More&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Health Care

Media

NYPD Warns About 'Wanted' Posters Targeting Finance Executives, And Crossed-Out UnitedHealthcare CEO (UPDATED)

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4323491-1&amp;h=1612110365&amp;u=https%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4323491-1&amp;h=540745686&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05964335&amp;a=Phase+2b+CORAL+trial">Phase 2b CORAL trial</a> in IPF patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The trial has reached 75% of the targeted enrollment,&nbsp;and topline results from the full trial continue to be expected in the first half of 2025.
&nbsp;
The SSRE analysis was conducted on the highest dose (108mg twice daily) in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment. Based on the SSRE analysis, it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater. The other two potential pre-specified outcomes of the SSRE analysis were an increase in the sample size or futility.

TRVI

Trevi Therapeutics' Chronic Cough Trial on Track After SSRE Outcome

Janus Henderson Triton Fund Q3 2024 Commentary

Janus Henderson Venture Fund Q3 2024 Commentary

Janus Henderson Concentrated All Cap Growth Managed Account Q3 2024 Commentary

Janus Henderson Global Life Sciences Fund Q3 2024 Commentary

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q3 2024 Commentary

Janus Henderson Global Select Fund Q3 2024 Commentary

TimesSquare U.S. Small Cap Growth Q3 2024 Commentary

Vaxcyte (PCVX) announced the initiation of the Phase 2 study of VAX-31 in healthy infants and that the first study participants have been dosed. Th...

Vaxcyte initiates Phase 2 study of VAX-31

Harbor Small Cap Growth Fund Q3 2024 Commentary

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target remain...

Vaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock Potential

AAIGF

AAPL

ABBV

ACLX

ADUS

AMGN

AMZN

AREA

ARGNF

ARGX

ASML

ASMLF

ASTS

ASTSW

AZNCF

BAESF

BHVN

BKNG

BLKB

BOOT

CBOE

CERT

COHR

DCNSF

DSGX

EBIT

EWCZ

FDMT

FORM

FROG

GDIV

GMED

GMVHF

GOOG

GOOGL

HAPI

HAPS

HAPY

HGER

ICUI

INFO

INNO

INSM

INSP

IRTC

JAAA

JBBB

JMBS

JSMD

JSML

LNTH

LOAR

LPLA

LRCX

LVMHF

LVMUY

MAPP

MDGL

MELI

MODG

MSFT

MTDR

MYRG

NONOF

NSSC

NVDA

ORCL

OSEA

OSIS

PCVX

PRMFF

PYFRF

RAMP

RENW

RKLIF

RPAY

SIFI

SIHY

SMSOF

SNYNF

SPXC

SRPT

SSNC

TECK

VLLU

VNLA

WINN

Press Releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Financing

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Earnings

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Comments

Vaxcyte

Noticias

Últimas noticias sobre Vaxcyte (NASDAQ:PCVX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL